Patents by Inventor Keigo Saito
Keigo Saito has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240018224Abstract: An object of the present invention is to provide: an anti-GPC3 antibody that recognizes an epitope different from that for existing antibodies (e.g., GC33 and GC199) and can specifically bind, even in the form of single chain antibody, to GPC3 localized on a cell membrane; CAR comprising the anti-GPC3 single chain antibody; an immunocompetent cell expressing the CAR; a gene of the anti-GPC3 antibody or a gene of the CAR; a vector comprising the anti-GPC3 antibody gene or the CAR gene; a host cell in which the vector has been introduced; a method for specifically detecting GPC3; and a kit for specifically detecting GPC3. An antibody comprising particular heavy chain CDR1 to CDR3 and particular light chain CDR1 to CDR3 defined in claim 1, and specifically binding to a human-derived GPC3 polypeptide specifically binds to GPC3 localized on a cell membrane. CAR-immunocompetent cells prepared on the basis of CAR comprising such single chain antibody are useful for cancer immunotherapy.Type: ApplicationFiled: June 15, 2023Publication date: January 18, 2024Applicants: Yamaguchi University, National Cancer Center, Noile-Immune Biotech, Inc.Inventors: Koji TAMADA, Yukimi SAKODA, Tetsuya NAKATSURA, Keigo SAITO
-
Patent number: 11718663Abstract: An object of the present invention is to provide: an anti-GPC3 antibody that recognizes an epitope different from that for existing antibodies (e.g., GC33 and GC199) and can specifically bind, even in the form of single chain antibody, to GPC3 localized on a cell membrane; CAR comprising the anti-GPC3 single chain antibody; an immunocompetent cell expressing the CAR; a gene of the anti-GPC3 antibody or a gene of the CAR; a vector comprising the anti-GPC3 antibody gene or the CAR gene; a host cell in which the vector has been introduced; a method for specifically detecting GPC3; and a kit for specifically detecting GPC3. An antibody comprising particular heavy chain CDR1 to CDR3 and particular light chain CDR1 to CDR3 defined in claim 1, and specifically binding to a human-derived GPC3 polypeptide specifically binds to GPC3 localized on a cell membrane. CAR-immunocompetent cells prepared on the basis of CAR comprising such single chain antibody are useful for cancer immunotherapy.Type: GrantFiled: January 10, 2018Date of Patent: August 8, 2023Assignees: Yamaguchi University, National Cancer Center, Noile-Immune Biotech, Inc.Inventors: Koji Tamada, Yukimi Sakoda, Tetsuya Nakatsura, Keigo Saito
-
Patent number: 10781249Abstract: An object of the present invention is to provide: an anti-GPC3 antibody that recognizes an epitope different from that for existing antibodies (e.g., GC33 and GC199) and can specifically bind, even in the form of single chain antibody, to GPC3 localized on a cell membrane; CAR comprising the anti-GPC3 single chain antibody; an immunocompetent cell expressing the CAR; a gene of the anti-GPC3 antibody or a gene of the CAR; a vector comprising the anti-GPC3 antibody gene or the CAR gene; a host cell in which the vector has been introduced; a method for specifically detecting GPC3; and a kit for specifically detecting GPC3. An antibody comprising particular heavy chain CDR1 to CDR3 and particular light chain CDR1 to CDR3 defined in claim 1, and specifically binding to a human-derived GPC3 polypeptide specifically binds to GPC3 localized on a cell membrane. CAR-immunocompetent cells prepared on the basis of CAR comprising such single chain antibody are useful for cancer immunotherapy.Type: GrantFiled: August 21, 2019Date of Patent: September 22, 2020Assignees: Yamaguchi University, National Cancer Center, Noile-Immune Biotech, Inc.Inventors: Koji Tamada, Yukimi Sakoda, Tetsuya Nakatsura, Keigo Saito
-
Patent number: 10730935Abstract: An object of the present invention is to provide: an anti-GPC3 antibody that recognizes an epitope different from that for existing antibodies (e.g., GC33 and GC199) and can specifically bind, even in the form of single chain antibody, to GPC3 localized on a cell membrane; CAR comprising the anti-GPC3 single chain antibody; an immunocompetent cell expressing the CAR; a gene of the anti-GPC3 antibody or a gene of the CAR; a vector comprising the anti-GPC3 antibody gene or the CAR gene; a host cell in which the vector has been introduced; a method for specifically detecting GPC3; and a kit for specifically detecting GPC3. An antibody comprising particular heavy chain CDR1 to CDR3 and particular light chain CDR1 to CDR3 defined in claim 1, and specifically binding to a human-derived GPC3 polypeptide specifically binds to GPC3 localized on a cell membrane. CAR-immunocompetent cells prepared on the basis of CAR comprising such single chain antibody are useful for cancer immunotherapy.Type: GrantFiled: August 21, 2019Date of Patent: August 4, 2020Assignees: Yamaguchi University, National Cancer Center, Noile-Immune Biotech, Inc.Inventors: Koji Tamada, Yukimi Sakoda, Tetsuya Nakatsura, Keigo Saito
-
Publication number: 20190367634Abstract: An object of the present invention is to provide: an anti-GPC3 antibody that recognizes an epitope different from that for existing antibodies (e.g., GC33 and GC199) and can specifically bind, even in the form of single chain antibody, to GPC3 localized on a cell membrane; CAR comprising the anti-GPC3 single chain antibody; an immunocompetent cell expressing the CAR; a gene of the anti-GPC3 antibody or a gene of the CAR; a vector comprising the anti-GPC3 antibody gene or the CAR gene; a host cell in which the vector has been introduced; a method for specifically detecting GPC3; and a kit for specifically detecting GPC3. An antibody comprising particular heavy chain CDR1 to CDR3 and particular light chain CDR1 to CDR3 defined in claim 1, and specifically binding to a human-derived GPC3 polypeptide specifically binds to GPC3 localized on a cell membrane. CAR-immunocompetent cells prepared on the basis of CAR comprising such single chain antibody are useful for cancer immunotherapy.Type: ApplicationFiled: August 21, 2019Publication date: December 5, 2019Applicants: YAMAGUCHI UNIVERSITY, NATIONAL CANCER CENTER, NOILE-IMMUNE BIOTECH, INC.Inventors: KOJI TAMADA, YUKIMI SAKODA, TETSUYA NAKATSURA, KEIGO SAITO
-
Publication number: 20190359698Abstract: An object of the present invention is to provide: an anti-GPC3 antibody that recognizes an epitope different from that for existing antibodies (e.g., GC33 and GC199) and can specifically bind, even in the form of single chain antibody, to GPC3 localized on a cell membrane; CAR comprising the anti-GPC3 single chain antibody; an immunocompetent cell expressing the CAR; a gene of the anti-GPC3 antibody or a gene of the CAR; a vector comprising the anti-GPC3 antibody gene or the CAR gene; a host cell in which the vector has been introduced; a method for specifically detecting GPC3; and a kit for specifically detecting GPC3. An antibody comprising particular heavy chain CDR1 to CDR3 and particular light chain CDR1 to CDR3 defined in claim 1, and specifically binding to a human-derived GPC3 polypeptide specifically binds to GPC3 localized on a cell membrane. CAR-immunocompetent cells prepared on the basis of CAR comprising such single chain antibody are useful for cancer immunotherapy.Type: ApplicationFiled: January 10, 2018Publication date: November 28, 2019Applicants: Yamaguchi University, National Cancer Center, Noile-Immune Biotech, Inc.Inventors: Koji TAMADA, Yukimi SAKODA, Tetsuya NAKATSURA, Keigo SAITO
-
Publication number: 20190066846Abstract: The present invention relates to a method for assisting recurrence risk prediction for hepatocellular carcinoma patients. The method comprises measuring glypican 3 (GPC3) peptide recognized by both a first monoclonal antibody and a second monoclonal antibody in a blood sample of a hepatocellular carcinoma patient, by contacting the sample with the first monoclonal antibody that recognizes a peptide having an amino acid sequence in the N-terminal side of GPC3 and the second monoclonal antibody that recognizes a peptide having an amino acid sequence in the C-terminal side of GPC3, and detecting the complex comprising GPC3 peptide, the first antibody and the second antibody.Type: ApplicationFiled: September 7, 2018Publication date: February 28, 2019Applicants: SYSMEX CORPORATION, NATIONAL CANCER CENTERInventors: Tetsuya NAKATSURA, Keigo SAITO, Masahiro MIURA, Kozo SUTO, Takuya IINO
-
Patent number: 9465030Abstract: Provided is a kit for diagnosing at a high reproducibility, said kit being produced by preparing a monoclonal antibody against GPC3 and a monoclonal antibody against SPARC that are superior in quality stability to commercially available and commonly employed antibodies, and using these antibodies.Type: GrantFiled: June 17, 2013Date of Patent: October 11, 2016Assignees: NATIONAL CANCER CENTER, LSIP, LLCInventors: Tetsuya Nakatsura, Keigo Saito
-
Publication number: 20150198598Abstract: Provided is a kit for diagnosing at a high reproducibility, said kit being produced by preparing a monoclonal antibody against GPC3 and a monoclonal antibody against SPARC that are superior in quality stability to commercially available and commonly employed antibodies, and using these antibodies.Type: ApplicationFiled: June 17, 2013Publication date: July 16, 2015Applicants: LSIP, LLC, NATIONAL CANCER CENTERInventors: Tetsuya Nakatsura, Keigo Saito
-
Patent number: D993898Type: GrantFiled: November 25, 2021Date of Patent: August 1, 2023Assignee: BRIDGESTONE CORPORATIONInventor: Keigo Saito
-
Patent number: D997855Type: GrantFiled: December 22, 2021Date of Patent: September 5, 2023Assignee: BRIDGESTONE CORPORATIONInventor: Keigo Saito
-
Patent number: D999151Type: GrantFiled: January 18, 2022Date of Patent: September 19, 2023Assignee: BRIDGESTONE CORPORATIONInventor: Keigo Saito
-
Patent number: D1001058Type: GrantFiled: January 18, 2022Date of Patent: October 10, 2023Assignee: BRIDGESTONE CORPORATIONInventor: Keigo Saito
-
Patent number: D1022864Type: GrantFiled: August 30, 2022Date of Patent: April 16, 2024Assignee: BRIDGESTONE CORPORATIONInventors: Keigo Saito, Shintaro Hayashi